Mapelor Ocas

Tamsulosin Hydrochloride, the active ingredient in Mapelor Ocas, is an alpha‑1 adrenergic receptor antagonist presented as an oral tablet for oral use. It is indicated for the treatment of benign prostatic hyperplasia and associated lower urinary tract symptoms in adult male patients.

GNH USA supplies Mapelor Ocas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Tamsulosin is used to manage conditions related to prostate enlargement and lower urinary tract dysfunction.

Benign prostatic hyperplasia (BPH): reduces prostate smooth‑muscle tone to improve urinary flow. Lower urinary tract symptoms associated with BPH: decreases urinary frequency, urgency and nocturia. Prostatic urinary retention: facilitates bladder emptying by relaxing the bladder neck.

Tamsulosin may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness or light‑headedness - Headache - Nasal congestion - Abnormal ejaculation, including retrograde ejaculation - Orthostatic hypotension

Serious or Rare Side Effects: - Severe hypotension or syncope - Priapism - Allergic reactions such as rash or angioedema - Cardiac arrhythmias - Hepatic dysfunction

When prescribing Tamsulosin, clinicians should consider several safety precautions to minimize risk.

Cardiovascular assessment: evaluate for orthostatic hypotension risk. Surgical caution: avoid use shortly before or after cataract or prostate surgery. Drug interaction review: monitor concomitant use of other alpha‑blockers or potent CYP3A4 inhibitors. Hepatic impairment: use with caution in patients with severe liver disease. Elderly patients: start at the lowest effective dose and monitor closely. Store at ambient temperature: keep in the original pack, protect from moisture.

Tamsulosin can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma levels. - Concurrent use of other alpha‑blockers (e.g., prazosin): risk of additive hypotension.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampin): may reduce effectiveness. - Antihypertensive agents: may enhance blood‑pressure‑lowering effect. - Diuretics: increase risk of orthostatic hypotension. - NSAIDs: may affect renal function when combined with Tamsulosin.